Abstract
Three patients receiving vincristine or binblastine developed recurrent laryngeal nerve paralysis, which resolved when the drug was withdrawn. The presence of mediastinal lymphadenopathy in patients with lymphoma may obscure the correct diagnosis, with the danger that the condition will produce respiratory distress if vinca alkaloid treatment is continued.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BOHANNON R. A., MILLER D. G., DIAMOND H. D. Vincristine in the treatment of lymphomas and leukemias. Cancer Res. 1963 May;23:613–621. [PubMed] [Google Scholar]
- Brook J., Schreiber W. Vocal cord paralysis: a toxic reaction to vinblastine (NSC-49842) therapy. Cancer Chemother Rep. 1971 Dec;55(5):591–593. [PubMed] [Google Scholar]
- Casey E. B., Jellife A. M., Le Quesne P. M., Millett Y. L. Vincristine neuropathy. Clinical and electrophysiological observations. Brain. 1973;96(1):69–86. doi: 10.1093/brain/96.1.69. [DOI] [PubMed] [Google Scholar]
- Holland J. F., Scharlau C., Gailani S., Krant M. J., Olson K. B., Horton J., Shnider B. I., Lynch J. J., Owens A., Carbone P. P. Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res. 1973 Jun;33(6):1258–1264. [PubMed] [Google Scholar]
- JOHNSON I. S., ARMSTRONG J. G., GORMAN M., BURNETT J. P., Jr THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS. Cancer Res. 1963 Sep;23:1390–1427. [PubMed] [Google Scholar]